Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Altace Plus Felodipine Ramipril/felodipine extended release Hypertension Do not list Complete
Alunbrig Brigatinib NSCLC Do not reimburse Complete
Alunbrig Brigatinib (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) Reimburse with clinical criteria and/or conditions Complete
Alvesco Ciclesonide asthma List Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Amvuttra vutrisiran Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) Reimburse with clinical criteria and/or conditions Complete
Anoro Ellipta Umeclidinium/vilanterol Chronic obstructive pulmonary disease List with criteria/condition Complete
Apidra Insulin glulisine Diabetes, Mellitus (Type 1 & 2) List in a similar manner to other drugs in class Complete
Apprilon Doxycycline monohydrate Rosacea Do not list Complete